

Ziphilus Appoints Trudy Vanhove as Non-Executive Director and Announces New York Office Opening

Ghent, Belgium and New York, US; 31 May 2024

Ziphilus, a leading biotechnology company developing self-amplifying RNA (saRNA) vaccines and therapeutics, is excited to announce the appointment of Trudy Vanhove, MD, PhD, MBA as Non-Executive Director. Additionally, the Company announces the opening of its New York office at the Genome Center located at 101 Avenue of the Americas.

Dr. Trudy Vanhove

Dr. Vanhove is an experienced biopharmaceutical executive and Venture Partner at Longitude Capital with over 25 years of experience in drug development, regulatory strategy, and corporate development. Dr. Vanhove previously served as Chief Medical Officer at Surrozen. Prior to Surrozen, she was Vice President of Medical Affairs and, subsequently, Search and Evaluation at Jazz Pharmaceuticals since 2012. Prior to Jazz Pharmaceuticals, she was Vice President, Medical Affairs at Depomed, Vice President Clinical Development at NeurogesX and a Medical Director and project team leader at XOMA. She began her career as a Medical Director at Abbott Laboratories in 1996.

Dr. Vanhove earned an MD and a PhD in pharmacology from the Catholic University in Leuven, Belgium. She completed a fellowship in clinical pharmacology at Stanford University and received an MBA from St. Mary's College in California. Dr. Vanhove has authored, or co-authored, dozens of peer-reviewed articles, and is an inventor on numerous patents.

Dr. Trudy Vanhove, upon her appointment, said: "I'm excited to bring my expertise in drug development, clinical strategy, and corporate development to Ziphilus, where tech and healthcare converge. I am eager to collaborate with Ziphilus' team to drive meaningful change in the vaccine industry." **Chris Cardon, CEO of Ziphilus continued:** " We are excited to welcome Trudy to the Ziphilus board as we expand our capabilities to enable development of our proprietary saRNA and carrier technology (LNP) platform. She brings extensive understanding of the strategic considerations and challenges associated with the biopharmaceutical industry, in addition to her venture, board and C-suite experience."

About Ziphilus

Ziphilus is a biotechnology company developing best-in-class vaccines and therapeutics based on its proprietary saRNA and carrier technology (LNP) platform to allow for a higher and prolonged protein/antigen expression at lower doses compared to conventional mRNA with reduced toxicity. This platform has the potential for a 'plug and play' approach offering the possibility of fast development/scale-up and production. These attributes make it well suited as platform to improve pandemic preparedness. Based in Ghent (Belgium) and New York (US) the companies present pipeline showcases strategic developments in infectious diseases, protein replacement therapies and a cutting-edge oncology program.

For more information, visit www.ziphilus.org, and follow us on [LinkedIn](#).

Heidestraat 19 - 9820 Merelbeke - Belgium

101 6th Avenue 3rd Floor, New York , NY 10013 USA